Cointime

Cytlimic

company

About

CYTLIMIC is a biotechnology company that develops immunotherapy products for the treatment of cancer, including a cancer peptide vaccine.

  • Higashi-shinagawa,Tokyo,Japan
  • 1 - 10

Highlights

Total Funding Amount
¥2.30B
Funding Rounds
3
Investors
3
Employee Profiles
7

Details

Last Funding Type
Seed
Industries
Biotechnology,Health Care,Pharmaceutical
Founded date
Dec 16, 2016
Number Of Employee
1 - 10
Operating Status
Active
Legal Name
Cytlimic Inc.

CYTLIMIC is a biotechnology company developing immunotherapy products for the treatment of cancer, including a cancer peptide vaccine. CYTLIMIC’s products aim to activate immune systems to attack cancer cells while enabling patients to maintain a high quality-of-life during treatment.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
¥2.30B
Cytlimic has raised a total of ¥2.30B in funding over 2 rounds. Their latest funding was raised on Aug 9, 2019 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Aug 9, 2019 Series B ¥1.30B 3 — — Detail
Dec 27, 2016 Seed — 1 — — Detail
Dec 19, 2016 Series A ¥1B 3 — — Detail

Investors

Number of Lead Investors
Number of Investors
—
3
Cytlimic is funded by 3 investors. Fast Track Initiative, Inc. and NEC Capital Solutions are the most recent investors.
Investor Name Lead Investor Funding Round
Fast Track Initiative, Inc. — Series B
NEC Capital Solutions — Series B
SMBC Venture Capital — Series B

Employee Profiles

Number of Employee Profiles
7
Cytlimic has 7 current employee profiles, including Board member Hiromichi Kimura
Hiromichi Kimura
Board member
Ken Nakamura
Board member
Yoshihide segawa
Executive
Minori Saito
Executive
Toi Shun
Board member
Show More
Cointime
Chủ Đề
Công Ty